Biotechnology
Technology
Health

BioMarin

$89.96
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.48 (-1.62%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell BioMarin and other stocks, options, ETFs, and crypto commission-free!

About

BioMarin Pharmaceutical Inc. Common Stock, also called BioMarin, is a biotechnology company, which develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Read More Its products include Aldurazyme, Brineura, Kuvan, Naglazyme, Palynziq and Vimizim. The company was founded by Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.

Employees
2,849
Headquarters
San Rafael, California
Founded
1997
Market Cap
16.30B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
1.15M
High Today
$91.82
Low Today
$89.79
Open Price
$91.42
Volume
414.32K
52 Week High
$106.74
52 Week Low
$75.81

Collections

Biotechnology
Technology
Health
Pharmaceutical
Medical
US
North America

News

Seeking AlphaMar 19

March 2019 Outlook For BioMarin

Still, the share price has floundered in the last month and remains down nearly 10% from 6 months ago. BMRN has recovered from a 12-month low in late 2018 on the strength of its pipeline promises and 2019 goals. BioMarin Pharmaceuticals Inc. (BMRN) continues to experience choppy price movements, even as it trades along the path of consolidation. Fundamental Outlook Part of what has produced some upside movements for BMRN at the beginning of the year was a January announcement of key milestones the compa...

21
Simply Wall StMar 12

Does BioMarin Pharmaceutical Inc.’s (NASDAQ:BMRN) CEO Pay Matter?

In 2005 Jean-Jacques Bienaimé was appointed CEO of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). First, this article will compare CEO compensation with compensation at other large companies. After that, we will consider the growth in the business. And finally – as a second measure of performance – we will look at the returns shareholders have received over the last few years. The aim of all this is to consider the appropriateness of CEO pay levels. View our latest analysis for BioMarin Pharmaceutical How Do...

42
Yahoo FinanceMar 12

See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

Biomarin Pharmaceutical Inc NASDAQ/NGS:BMRN View full report here! Summary ETFs holding this stock have seen outflows over the last one-month Bearish sentiment is low Bearish sentiment Short interest | Positive Short interest is low for BMRN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flow ETF/Index owne...

6

Earnings

-$0.26
-$0.16
-$0.07
$0.03
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected Apr 24, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.